ArticleThe Journal of international medical research2026
Guillain-Barré syndrome triggered by acute hepatitis E virus infection: The first reported case from Egypt.
Article in The Journal of international medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A man in his early 50 s presented with a 7-day history of progressive, symmetrical weakness that began in the lower limbs and ascended to involve the upper limbs. His symptoms were accompanied by distal paresthesia and complete areflexia. Three weeks prior to presentation, he experienced a self-limiting febrile illness associated with dark urine and elevated transaminase levels, which resolved spontaneously. On admission, laboratory investigations demonstrated elevated liver enzyme levels and positive anti-hepatitis E virus Immunoglobulin M antibodies, confirming acute hepatitis E virus infection. Nerve conduction studies were consistent with the acute inflammatory demyelinating polyneuropathy variant of Guillain-Barré syndrome. The patient was treated with intravenous immunoglobulin (0.4 g/kg/day for 5 days) and was closely monitored for respiratory and autonomic complications. Gradual neurological improvement was observed, along with normalization of liver function tests. To the best our knowledge, this case represents the first documented occurrence of hepatitis E virus-associated Guillain-Barré syndrome in Egypt after a careful review of the literature. It underscores the importance of considering hepatitis E virus infection in the differential diagnosis of Guillain-Barré syndrome, particularly in patients presenting with elevated liver enzymes or a recent history of hepatitis in hepatitis E virus-endemic regions. Early recognition and prompt initiation of immunotherapy may improve neurological recovery and clinical outcomes in this rare but clinically significant association.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.